Third Rock Ventures
Third Rock Ventures invests in transformational life science companies that show high growth potential
Business Model:
Revenue: $20M
Employees: 11-50
Rankings
Industries / Tags:
Detailed Third Rock Ventures Information
Geographic Data
Address: 29 Newbury St
City: Boston
State: MA
Zip: 02116
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$3B
Social
Linkedin
Crunchbase
Metrics
3,968,946Website Global Rank
3,036Website Monthly Traffic
Twitter Followers
Description
Third Rock Ventures invests in transformational life science companies that show high growth potential and are well-positioned to make a difference in the marketplace.
Contact Phone:
+16175852000
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 3/2023 | Rapport Therapeutics | Series A | 0 |
| 4/2014 | PanOptica | Series B | 45M |
| 9/2016 | Relay Therapeutics | Series A | 57M |
| 5/2016 | PanOptica | Series B | 23.9M |
| 10/2013 | SAGE Therapeutics | Series B | 20M |
| 1/2017 | Neon Therapeutics | Series B | 70M |
| 9/2020 | Casma Therapeutics | Series B | 50M |
| 5/2018 | Insitro | Series A | 100M |
| 3/2020 | Nurix Therapeutics | Private Equity Round | 120M |
| 11/2020 | Decibel Therapeutics | Series D | 82.2M |
| 7/2012 | Bluebird Bio | Series D | 0 |
| 3/2023 | CARGO Therapeutics | Series A | 0 |
| 6/2012 | Igenica | Series C | 33M |
| 5/2022 | Terremoto Biosciences | Series A | 0 |
| 5/2021 | Flare Therapeutics | Series A | 82M |
| 7/2013 | Edimer | Series B | 18M |
| 4/2014 | Kala Pharmaceuticals | Series B | 0 |
| 3/2012 | Kala Pharmaceuticals | Private Equity Round | 7.2M |
| 1/2014 | Blueprint Medicines | Series B | 25M |
| 1/2015 | CytomX Therapeutics | Series C | 20M |
| 3/2021 | Asher Bio | Series A | 0 |
| 6/2012 | Motus Therapeutics | Series B | 25M |
| 8/2009 | Constellation Pharmaceuticals | Series A | 17.2M |
| 5/2011 | YourBio Health | Series A | 4.5M |
| 3/2010 | Sesen Bio, Inc. | Series A | 35M |
| 10/2010 | NinePoint Medical | Series A | 33M |
| 7/2011 | Larimar Therapeutics | Series C | 33M |
| 12/2021 | Ambys Medicines | Series A | 47M |
| 12/2011 | Ember Therapeutics | Series A | 34M |
| 5/2014 | Nurix Therapeutics | Series B | 25.1M |
| 7/2020 | Thrive Earlier Detection | Series B | 0 |
| 3/2013 | Corvia Medical | Series C | 10.7M |
| 4/2019 | Insitro | Series A | 100M |
| 11/2022 | Casma Therapeutics | Series C | 46M |
| 10/2021 | Cedilla Therapeutics | Series B | 0 |
| 9/2021 | Asher Bio | Series B | 0 |
| 6/2018 | Decibel Therapeutics | Series C | 55M |
| 5/2022 | MOMA Therapeutics | Series B | 0 |
| 11/2012 | Motus Therapeutics | Series B | 8M |
| 3/2020 | Element Science | Series C | 145.6M |
| 3/2013 | Janssen Global Services | Venture Round | 13.5M |
| 11/2011 | Agios | Series C | 78M |
| 5/2012 | Nurix Therapeutics | Seed Round | 3.1M |
| 10/2012 | Cibiem, Inc. | Series A | 10M |
| 7/2012 | CytomX Therapeutics | Series B | 11M |
| 2/2016 | Pliant Therapeutics | Series A | 0 |
| 7/2013 | Alcresta | Series B | 10M |
| 12/2010 | Cibiem, Inc. | Seed Round | 3M |
| 12/2015 | Constellation Pharmaceuticals | Series E | 55M |
| 2/2014 | Voyager Therapeutics | Series A | 45M |
| 3/2013 | Nurix Therapeutics | Venture Round | 5.3M |
| 1/2014 | Igenica | Series C | 14M |
| 4/2008 | Constellation Pharmaceuticals | Series A | 32M |
| 12/2016 | Goldfinch Biopharma | Series A | 55M |
| 3/2010 | Larimar Therapeutics | Series B | 28M |
| 3/2014 | SAGE Therapeutics | Series C | 38M |
| 6/2010 | Ablexis | Series A | 12M |
| 12/2012 | Larimar Therapeutics | Series D | 21M |
| 1/2022 | Septerna | Series A | 100M |
| 5/2019 | Thrive Earlier Detection | Series A | 110M |
| 7/2014 | Corvia Medical | Series D | 34M |
| 4/2011 | Bluebird Bio | Series C | 30M |
| 6/2021 | Abata Therapeutics | Series A | 0 |
| 9/2012 | Foundation Medicine | Series B | 42.5M |
| 5/2020 | Insitro | Series B | 143M |
| 4/2013 | Afferent Pharmaceuticals | Series B | 5M |
| 8/2018 | Ambys Medicines | Series A | 60M |
| 2/2013 | Kala Pharmaceuticals | Series A | 0 |
| 4/2011 | Janssen Global Services | Series B | 18.4M |
| 9/2010 | Motus Therapeutics | Series A | 19M |
| 8/2015 | Editas Medicine | Series B | 0 |
| 2/2017 | Rhythm Pharmaceuticals | Venture Round | 41M |
| 8/2015 | Rhythm Metabolic | Series A | 40M |
| 1/2012 | Warp Drive Bio | Private Equity Round | 125M |
| 10/2020 | Cedilla Therapeutics | Series B | 57.6M |
| 10/2008 | Alnara Pharmaceuticals | Series A | 20M |
| 3/2022 | Celsius Therapeutics | Series B | 0 |
| 5/2017 | Magenta Therapeutics | Series B | 0 |
| 12/2017 | Relay Therapeutics | Series B | 63M |
| 4/2011 | Blueprint Medicines | Series A | 40M |
| 10/2011 | Foundation Medicine | Series A | 33.5M |
| 11/2014 | Blueprint Medicines | Series C | 50M |
| 8/2014 | MyoKardia | Venture Round | 0 |
| 4/2018 | Constellation Pharmaceuticals | Series F | 0 |
| 3/2021 | Insitro | Series C | 400M |
| 2/2019 | Maze Therapeutics | Series A | 191M |
| 3/2023 | Flare Therapeutics | Series B | 0 |
| 4/2018 | Revolution Medicines | Series B | 56M |
| 4/2020 | MOMA Therapeutics | Series A | 86M |
| 10/2015 | Neon Therapeutics | Series A | 55M |
| 3/2017 | Tango Therapeutics | Series A | 55M |
| 9/2012 | MyoKardia | Series A | 38M |
| 6/2009 | Edimer Pharmaceuticals | Series A | 22M |
| 6/2012 | Global Blood Therapeutics | Series A | 40.7M |
| 2/2015 | Revolution Medicines | Series A | 45M |
| 11/2013 | Editas Medicine | Series A | 43M |
| 5/2012 | Sesen Bio, Inc. | Series A | 20M |
| 12/2014 | Allena Pharmaceuticals | Series B | 0 |
| 3/2018 | Rheos Medicines | Series A | 60M |
| 7/2019 | Revolution Medicines | Series C | 100M |
| 3/2014 | Element Science | Series A | 12.5M |
| 2/2013 | Jounce Therapeutics | Series A | 47M |
| 11/2011 | Allena Pharmaceuticals | Series A | 15M |
| 4/2012 | Alcresta | Series A | 10M |
| 12/2009 | Afferent Pharmaceuticals | Series A | 23M |
| 9/2010 | CytomX Therapeutics | Series B | 30M |
| 7/2008 | Agios | Series A | 33M |
| 5/2018 | Casma Therapeutics | Series A | 58.5M |
| 5/2018 | Celsius Therapeutics | Series A | 65M |
| 1/2011 | PanOptica | Series A | 30M |
| 7/2017 | Constellation Pharmaceuticals | Series E | 48.5M |
| 8/2016 | Element Science | Series B | 25M |
| 10/2011 | Topica Pharmaceuticals | Series B | 27M |
| 12/2016 | Revolution Medicines | Series A | 25M |
| 6/2010 | Constellation Pharmaceuticals | Series B | 22.3M |
| 6/2011 | Constellation Pharmaceuticals | Series B | 15M |
| 12/2013 | Soffio Medical | Seed Round | 3M |
| 3/2010 | Bluebird Bio | Series B | 35M |
| 12/2020 | Faze Medicines | Series A | 81M |
| 4/2018 | Cedilla Therapeutics | Series A | 56.2M |
| 10/2017 | PanOptica | Series B | 11M |
| 6/2011 | Lotus Tissue Repair | Series A | 26M |
| 3/2014 | NinePoint Medical | Series B | 34M |
| 7/2016 | Fulcrum Therapeutics | Series A | 55M |
| 10/2011 | SAGE Therapeutics | Series A | 35M |
| 11/2016 | Magenta Therapeutics | Series A | 48.5M |
| 10/2015 | Decibel Therapeutics | Series A | 52M |
| 5/2022 | Terremoto Biosciences | Series A | 0 |
| 5/2022 | MOMA Therapeutics | Series B | 0 |
| 3/2022 | Celsius Therapeutics | Series B | 0 |
| 1/2022 | Septerna | Series A | 0 |
| 12/2021 | Ambys Medicines | Series A | 0 |
| 10/2021 | Cedilla Therapeutics | Series B | 0 |
| 9/2021 | Asher Bio | Series B | 0 |
| 6/2021 | Abata Therapeutics | Series A | 0 |
| 5/2021 | Flare Therapeutics | Series A | 0 |
| 3/2021 | Asher Bio | Series A | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
